Agenus Inc.
Agenus Inc. (Nasdaq: AGEN) is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease, with its primary business in immuno-oncology. Its lead program combines botensilimab, an anti-CTLA-4 antibody, with balstilimab, an anti-PD-1 antibody; the… From the company’s description.
Over the twelve months to Sep 30, 2026, Agenus Inc. reported revenue of $133.95M, up 25.4% from a year earlier, and net income of $30.75M. Its operating margin was 38.9%, and operations used $103.86M in cash. In fiscal 2025, it reported revenue of $114.20M, up 10.4% from fiscal 2024, and a net loss of $3.08M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Agenus Inc. does
In the company’s own words
Agenus Inc. (Nasdaq: AGEN) is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease, with its primary business in immuno-oncology. Its lead program combines botensilimab, an anti-CTLA-4 antibody, with balstilimab, an anti-PD-1 antibody; the investigational therapies are being studied across several cancer types, with a global Phase 3 trial in refractory colorectal cancer. Agenus also owns or controls earlier-stage antibody programs and operates SaponiQx, a subsidiary developing saponin-based vaccine adjuvants, including cultured plant cell-derived QS-21 STIMULON. The company uses internal discovery, translational, clinical and regulatory capabilities alongside collaborations, and its portfolio includes partnered antibody programs and an equity investment in clinical-stage cell-therapy company MiNK Therapeutics. Following a 2024 strategic realignment, Agenus prioritized botensilimab and balstilimab while pausing certain other activities. It had 81 employees as of February 28, 2026, and began recognizing revenue in 2025 from authorized patient-access programs. Its website is www.agenusbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1098972
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Agenus Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Agenus Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Agenus Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Agenus Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Agenus Inc.'s last four quarterly filings that the numbers alone won't show?”